| Literature DB >> 27145803 |
Hyoung-Gon Ko1, Seog-Bae Oh2, Min Zhuo3, Bong-Kiun Kaang4.
Abstract
Autism spectrum disorder is a debilitating mental illness and social issue. Autism spectrum disorder patients suffer from social isolation, cognitive deficits, compulsive behavior, and sensory deficits, including hyposensitivity to pain. However, recent studies argued that autism spectrum disorder patients show physiological pain response and, in some cases, even extremely intense pain response to harmless stimulation. Recently, Shank gene family was reported as one of the genetic risk factors of autism spectrum disorder. Thus, in this study, we used Shank2(-) (/) (-) (Shank2 knock-out, KO) mice to investigate the controversial pain sensitivity issue and found that Shank2 KO mice showed reduced tactile perception and analgesia to chronic pain.Entities:
Keywords: Autism; nociception; pain; shank2
Mesh:
Substances:
Year: 2016 PMID: 27145803 PMCID: PMC4956181 DOI: 10.1177/1744806916647056
Source DB: PubMed Journal: Mol Pain ISSN: 1744-8069 Impact factor: 3.395
Figure 1.Shank2 KO mice show impaired basal tactile perception and acute pain response. (a) Experimental schedule to evaluate pain response in Shank2 KO mice. HP, hot plate; TF, tail flick. (b) Measurement of basal mechanical withdrawal threshold in Shank2 KO mice. Increasing force was applied on the left hind paw using electronic von Frey filaments and the latency to the withdrawal response was measured automatically (n = 29 for WT, n = 30 for Shank2 KO, unpaired t-test, t57 = 5.635, *** p < 0.001). (c, d) Acute pain perception in Shank2 KO mice was evaluated by the hot plate (c) and tail flick (d) tests (hot plate test, n = 10 for each group, unpaired t-test, t18 = 3.134, ** p < 0.01; tail flick test, n = 19 for WT, n = 21 for Shank2 KO, unpaired t-test, t38 = 3.092, ** p < 0.01).
Figure 2.Shank2 KO mice show impaired induction of chronic pain. (a) CFA was injected in the left hind paw sole after measuring basal mechanical withdrawal threshold (Day 0). Thresholds were reduced at Day 3 and Day 7 after CFA injection in both WT and Shank2 KO groups; however, there was no significant difference (n = 10 for WT, n = 9 for Shank2 KO; repeated measure two-way ANOVA: effect of time, F(2,36) = 15.95, p < 0.001; effect of genotype, F(1,36) = 3.456, p > 0.05; effect of interaction, F(2,36) = 0.1038, p > 0.05). (b) After measuring basal allodynia response (Day 0), CFA was injected in the left hind paw dorsum and again allodynia response was measured at Day 3 and Day 7 after CFA injection (n = 9 for each group, repeated measure two-way ANOVA followed by Bonferroni posttest: effect of time, F(2,16) = 31.73, p < 0.001; effect of genotype, F(1,16) = 18.34, p < 0.001; effect of interaction, F(2,16) = 5.165, p < 0.05, posttest ** p < 0.01, *** p < 0.001; one-way ANOVA followed by Tukey’s multiple comparison test for Shank2 KO, F(2,16) = 6.306, p < 0.01, posttest ## p < 0.01). (c) After measuring basal allodynia response (Day 0), the left CPN was ligated to induce neuropathic pain and allodynia response was measured again at Day 3 and Day 7 after CPN ligation (n = 9 for WT, n = 10 for Shank2 KO; repeated measure two-way ANOVA followed by Bonferroni posttest: effect of time, F(2,34) = 11.27, p < 0.001; effect of genotype, F(1,34) = 58.74, p < 0.001; effect of interaction, F(2,34) = 9.696, p < 0.001, posttest *** p < 0.001). Interestingly, Shank2 KO mice showed decreased allodynia response after CPN ligation.